Table of Contents

Rituximab added to front-line CHOP significantly improves time to treatment failure and response duration in all FLIPI risk groups of patients with advanced-stage follicular lymphoma

NE Oncology Issue - July 2008 Meenakshi Kashyap Background Hiddemann and colleagues1 have conclusively demonstrated that the addition of rituximab to front-line therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) results in a significantly...

Download Journal

oncol_issue

Contributors

dr-kuruvilla
John Kuruvilla, MD
Dr. John Kuruvilla is an Assistant Professor of Medicine at the University of Toronto and a Clinical Investigator in the Department of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto. He is a hematologist and member of the Lymphoma Program and the Autologous and Allogeneic Stem Cell Programs. His
research interests include novel drug development in lymphoid malignancies as well as the study of stem cell
transplant strategies and clinical trials in these disorders.

dr-lemieux
Bernard Lemieux, MD, FRCPC
Dr. Lemieux is a Clinical Assistant Professor at the University of Montreal, and a Medical Oncologist in Hematology at the university’s hospital centre (CHUM). He is the Medical Director of the Hematology Tumour Program and of the Lymphoproliferative Disease Clinic at CHUM. He is also co-director of CHUM’s Clinical Oncology Research Program.

dr-Sehn
Laurie H. Sehn, MD, MPH
Dr. Laurie Sehn is a Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia. She has been a Medical Oncologist and Clinical Investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of the Lymphoma Foundation Canada (LFC) since 2002, and is now the Director of Research Fellowships for the LFC. Dr. Sehn has also served as an expert reviewer for multiple medical journals, and is currently on the editorial boards of Leukemia & Lymphoma and the Journal of Clinical Oncology. Her research interests include all of the lymphoid cancers, with particular interest in the biology and treatment of large-cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.